A spatial similarity of stereochemical environments formed by amino acid residues defines a common epitope of two non-homologous proteins

Kentaro Nakashima1, Shintaro Iwashita1,2, Takehiro Suzuki3, Chieko Kato1, Toshiyuki Kohno4, Yasutomi Kamei5, Motoki Sasaki6, Osamu Urayama7, Yoshiko Ohno-Iwashita2, Naoshi Dohmae3 & Si-Young Song1

It is critical for development of high-quality antibodies in research and diagnostics to predict accurately their cross-reactivities with “off-target” molecules, which potentially induce false results. Herein, we report a good example of such a cross-reactivity for an off-target due to a stereochemical environment of epitopes, which does not simply depend on amino acid sequences. We found that significant subpopulation of a polyclonal peptide antibody against Bcnt (Bucentaur) (anti-BCNT-C antibody) cross-reacted with a completely different protein, glutamine synthetase (GS), and identified four amino acids, GYFE, in its C-terminal region as the core amino acids for the cross-reaction. Consistent with this finding, the anti-BCNT-C antibody strongly recognized endogenously and exogenously expressed GS in tissues and cultured cells by Western blotting and immunohistochemistry. Furthermore, we elucidated that the cross-reaction is caused by a spatial similarity between the stereochemical environments formed by amino acid residues, including the GYFE of GS and the GYIE of Bcnt, rather than by their primary sequences. These results suggest it is critical to comprehensively analyze antibody interactions with target molecules including off-targets with special attention to the physicochemical environments of epitope-paratope interfaces to decrease the risk of false interpretations of results using antibodies in science and clinical applications.

Antibodies (Abs) are very powerful tools not only in basic research but also in clinical application of molecular targeted therapies for cancer1–3 and autoimmune diseases such as rheumatoid arthritis4,5. Antibody (Ab) drugs are a rapidly growing class of biopharmaceuticals and a large number of novel promising Abs such as nivolumab and pembrolizumab have been generated during the last few years. To efficiently develop high quality Abs for research use as well as Ab drugs and vaccines, it is critical not only to design immunogens that generate Abs with quite specific immunoreactivity for on-target molecules but also to predict more accurately cross-reactivities of Abs with “off-targets”, which potentially induce side effects in therapies using Abs and vaccines6. The amino acid sequences of epitopes have been considered to be a primary basis for specific immunoreactions of Abs with target molecules. However, in addition to Abs against proteins, those against nonprotein molecules, such as anti-DNA and anti-phospholipid Abs, are also well known. On the other hand, recent reports demonstrated that a multispecific
monoclonal Ab recognizes completely different linear epitope sequences with high affinity7, and progress is proceeding toward development of therapies by intentionally using such a dual-specific Ab8. These examples are difficult to understand from a simple grasp of epitopes based on only their amino acid sequences. The epitopes are conventionally classified into two groups, linear or sequential and discontinuous or conformational9,10. Such a conventional classification based on amino acid sequences is useful to simply explain epitopes of proteins but insufficient to more accurately understand epitopes in antigen-Ab interactions such as the above-described examples because these examples indicate that Ab recognition of target molecules is based on the physicochemical environment of epitopes and does not necessarily depend on their linear amino acid sequences. Accordingly, it is necessary to have a more comprehensive understanding of Ab specificities on the basis of physicochemical features of epitopes. In this report, we present a didactic example to consider these points.

We identified the Bcnt (Bucentaur)/Cfdp1 (craniofacial developmental protein 1) protein family, which probably function as a component of chromatin remodeling complex by the study of the yeast ortholog Swc511. Previously, we raised an Ab against a peptide of a C-terminal region of BCNT (called BCNT-C), EELAIHNRGKEGYIERKA, which is evolutionarily conserved from yeast to humans12. This anti-BCNT-C Ab detected doublet bands of 43/45 kDa by Western blot analysis of proteins extracted from bovine and rat brains. We tried to isolate them by immunoprecipitation and identify them by mass spectrometry. Surprisingly, we obtained the unexpected result that the 43 kDa protein is glutamine synthetase (GS: NP_001035564.1); EC 6.3.1.2, also known as γ-glutamate: ammonia ligase13,14, an enzyme entirely unrelated to Bcnt, which catalyzes the ATP-dependent condensation of glutamate and ammonia to form glutamine. The anti-BCNT-C Ab can specifically detect not only recombinant GS but also endogenous GS in rat brain. This quite specific reactivity of the Ab with an off-target molecule prompted us to seek a common epitope between GS and Bcnt to elucidate a chemical basis for the cross-reactivity of the anti-BCNT-C Ab with GS. We report here that the core amino acids of the common epitope causing the cross-reaction were identified as GYFE in GS and GYIE in Bcnt. Also, we discuss here the significance of physico- or stereochemical environments in epitope–paratope10 or protein–protein interactions15 and findings on the proteome-wide analyses of epitopes9.

Results
Detection of the 43 kDa protein by anti-BCNT-C Ab. Previously, we reported detection of strong doublet bands of 43/45 kDa by Western blot analysis of proteins extracted from bovine and rat brains with the anti-BCNT-C Ab12. This Ab reproducibly detected the 43/45 kDa proteins in mouse brain and HEK293T cells transfected with mouse bcnt expression vector, as shown on the top of each lane. Note that a strong signal of the 43 kDa in mouse brain extracts was detected only by anti-BCNT-C Ab, while the recombinant mouse Bcnt protein was detected by all Abs.

---

**Figure 1.** The 43 kDa protein as a major reactant in Western blotting with the anti-BCNT-C Ab. Western blotting was conducted with the polyclonal anti-BCNT-C, mBcnt-N and Bcnt-Cter Abs, as shown under each figure, using extracts of mouse brain and HEK293T cells transfected with mouse bcnt expression vector, as shown on the top of each lane. Note that a strong signal of the 43 kDa in mouse brain extracts was detected only by anti-BCNT-C Ab, while the recombinant mouse Bcnt protein was detected by all Abs.
Ab detected the recombinant Bcnt similarly as the anti-BCNT-C Ab, whereas they did not detect the 43/45 kDa proteins (Fig. 1). These results clearly indicate that 43/45 kDa proteins are specifically detected by only the anti-BCNT-C Ab, not the anti-Bcnt-Cter and the anti-mBcnt-N Ab. In addition to this discrepancy and different molecular sizes of these immunoreactants from the recombinant Bcnt (Fig. 1 and see Supplementary Fig. S2), their very high immunoreactivity prompted us to identify these proteins at the molecular level.

Identification of the 43 kDa protein. We found that we could immunoprecipitate the 43 kDa protein, but not the 45 kDa protein, from the extracts of bovine brain and rat olfactory bulb when the extracts were boiled once in SDS, whereas we failed using a conventional Radioimmunoprecipitation assay (RIPA) buffer (see Supplementary Fig. S3). Using this method, we isolated the 43 kDa protein from the extracts by ammonium sulfate precipitation, phenyl-sepharose chromatography (see Supplementary Fig. S4A), and immunoprecipitation using agarose beads coupled with the anti-BCNT-C Ab (see Supplementary Fig. S4B). Three broad Coomassie Brilliant Blue (CBB)-positive bands with a molecular mass of 43, 55 or 65 kDa, respectively, were detected on SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) of immunoprecipitated proteins (Fig. 2). Protein mixtures contained in each separate band were subjected to LC-MS/MS analysis. Surprisingly, results from the analyses showed that glutamine synthetase (GS) was detected in all three bands, whereas no Bcnt fragment was detected in any analyzed band except for the GKEGYIER that was derived from the immunogen peptide used for elution of bound proteins from the affinity beads. In particular, GS having a calculated molecular mass of 42 kDa was detected as a major component in the 43 kDa band together with gamma actin, alpha skeletal muscle actin, and tubulin alpha-1B chain, where the coverage of GS by the tryptic peptides was 76.9% (see Supplementary Fig. S5A, B and Table S2). Detection of GS in these three distinct bands was probably caused by a mobility shift due to its modification by ubiquitination. These data suggest that GS, a protein not homologous to Bcnt, was the most promising candidate for the 43 kDa protein recognized by the polyclonal anti-BCNT-C Ab. It should be noted that the anti-BCNT-C Ab with cross-reactivity to GS was generated in seven of eight guinea pigs immunized with the 18-mer BCNT-C peptide in two independent immunizations, making it unlikely that generation of the anti-BCNT-C Ab with such a cross-reactivity was accidental.

Recognition of glutamine synthetase by the anti-BCNT-C Ab. To examine whether the anti-BCNT-C Ab really cross-reacts with GS, we carried out Western blot analysis using two distinct GS sources: a purified recombinant His-tagged human GS expressed in Escherichia coli (E. coli) and extracts of skeletal muscle of FOXO1-transgenic mice, which preferentially increase the mRNA and protein expressions of GS. These results demonstrate that the Ab detected the same size band at a comparable level as a canonical anti-GS Ab does (see Supplementary Fig. S6). Considering the effect of a His-tag added to a recombinant protein, we also expressed tag-free recombinant mouse GS and Bcnt or those with various tags, such as Flag, enhanced green
fluorescent protein (EGFP), and mCherry, in HEK293T cells to examine multilaterally the cross-reactivity of the anti-BCNT-C Ab with GS, and then these recombinant proteins were analyzed by Western blotting and immunocytochemistry. Because the anti-BCNT-C Ab recognized GS regardless of type or presence or absence of tags, representative results of tag-free and Flag-tagged mGS and mBcnt are shown in Fig. 3A, which clearly show that the anti-BCNT-C Ab specifically recognized both Bcnt and GS. Additionally, we further examined by immunocytochemistry whether the cross-reactivity to GS in situ is specific for the anti-BCNT-C Ab using the anti-Bcnt-Cter Ab and the anti-mBcnt-N Ab. While the anti-BCNT-C Ab can specifically immunostain exogenously expressed GS in HEK cells, but not the two other anti-Bcnt Abs (Fig. 3B). The anti-BCNT-C Ab shows a strong immunoreactivity in situ as shown by positive immunostaining of Bergmann glia, a type of astrocyte, in the rat cerebellum (see Supplementary Fig. S7), which is consistent with previous reports that GS is a marker of astrocytes19. Other data are described in supporting information, which show that some characteristics of the immunoreactant recognized by the anti-BCNT-C Ab are also consistent with those previously reported for GS (see Supplementary Fig. S8, refs20,21). Because we confirmed that the anti-BCNT-C Ab really recognizes GS, a protein not homologous to Bcnt, we conducted epitope analysis of GS to investigate the mechanisms for such a peculiar cross-reactivity.

**Epitope analysis of GS for cross-reactivity of the anti-BCNT-C Ab.** First, we prepared several deletion mutants of GS protein in E. coli to identify the region recognized by the anti-BCNT-C Ab on a GS molecule. Representative results of Western blotting are shown in Fig. 4A. While a clear positive reaction was detected for a GS mutant lacking almost half of the N-terminal amino acids (D2), no reaction was observed for a GS mutant lacking C-terminal amino acids 332–373 (D1), strongly suggesting that the epitope is localized in the C-terminal region of GS. To further narrow down the predicted epitope region, we employed competition experiments using four peptides with short overlapping amino acids (P1–P4 in Fig. 4B, upper panel, see Supplementary Fig. S9) derived from the C-terminal region of GS. Western blot analysis using the preincubated anti-BCNT-C Ab with each peptide or the antigen peptide showed that only P1 among the four peptides strongly inhibited the cross-reactivity of the Ab with GS similar to the antigen peptide (Fig. 4B, lower panel). These results strongly suggest that the epitope must be included in the P1 peptide sequence. Furthermore, to identify key amino acids involved in the cross-reaction, we prepared graded deletion mutants of GS and examined their reactivity with the anti-BCNT-C Ab by Western blotting. As shown in Fig. 4C, the cross-reactivity was clearly observed for the Del-338 mutant but was conspicuously absent for the Del-336 mutant. This result indicates that key amino acids for the cross-reaction are limited to RTVGQEKKGYFE in the P1 peptide sequence. We noticed that KKGYFE of GS is similar to KEGYIE of antigen peptide for anti-BCNT-C Ab, especially GYFE of GS and GYIE of Bcnt (Fig. 4C, lower left), and we examined the cross-reactivity with a focus on GYFE of GS using alanine substitution mutants.
of GS. Whereas weak but significant reactivity was detected for the F337A mutant, no reactivity was detected for other alanine substitution mutants including E338A (Fig. 4D). These results clearly show that GYFE (hereinafter called “the core amino acids”) is required for the cross-reactivity of the anti-BCNT-C Ab with GS. As shown in Fig. 4D, mutant A4A also lacked reactivity with the Ab, suggesting the possibility that K333 and/or K334 may be included in the epitope.

Evaluation of the affinity of the anti-BCNT-C Ab to GS and BCNT. Next, we evaluated the affinity of the anti-BCNT-C Ab to GS and BCNT by semi-quantitative Western blotting of Flag-tagged mouse GS (F-mGS) and Bcnt (F-mBcnt) normalized with an anti-Flag-tag Ab (Fig. 5). A subpopulation of the polyclonal anti-BCNT-C Ab, which cross-reacts with GS, was fractionated by a column of agarose resin cross-linked with GS(332–346) peptide including the core amino acids, GYFE (shown in Fig. 5A). The binding fraction (GYFE fraction) was isolated in about 20% yield as a protein weight, indicating that the subpopulation of the polyclonal anti-BCNT-C Ab cross-reacting with the core amino acids, GYFE, of GS occupied about one fifth. Consistent with these results, the normalized immunoreactivity of the anti-BCNT-C Ab for F-mGS is estimated to be approximately one fifth compared with that for F-mBcnt (Fig. 5A, left). Furthermore, the GYFE fraction from the anti-BCNT-C Ab reacted to F-mGS and F-mBcnt with equivalent immunoreactivity (Fig. 5A, right), whereas the flow-through fraction did not react to F-mGS (Fig. 5A, middle). These results suggest that the subpopulation of the polyclonal anti-BCNT-C Ab cross-reacting with GS, derives from only Ab molecules recognizing epitopes including the core amino acids, GYFE. On the other hand, the immunoreactivity of the GYFE fraction was inhibited with a peptide EELAIHNGKEGYIERKA-NH2, BCNT-C (GYIE) in Fig. 5B, but not with its mutant replacing GYIE with Alanine, BCNT-C (All-Ala) in Fig. 5B. This result shows that the subpopulation of the polyclonal anti-BCNT-C Ab cross-reacting with GYFE of GS specifically reacts to GYIE of Bcnt.

Spatial similarity of stereochemical environment between GS epitope and BCNT-C antigen. To understand the similar immunoreactivities of the anti-BCNT-C Ab against both GS and Bcnt in spite of the
We have previously demonstrated that the anti-BCNT-C Ab recognizes a specific epitope, GYFE, found in the C-terminal of GS. In this study, we aimed to identify the core amino acid sequence, GYFE, localized in a limited region of the C-terminal of GS, that is necessary for the cross-reactivity of the anti-BCNT-C Ab (Fig. 4C). We conjectured that this sequence has an epitope in GS that is necessary for the cross-reactivity of the anti-BCNT-C Ab with GS. To investigate how F337 actually participates in the antigen-Ab interaction, we prepared substitution mutants of F337 of GS with various amino acids having different steric bulks (the amount of space that side chain atoms of amino acids occupy) or polarities and tried to semi-quantitatively analyze the effect of those substitutions on stereochemical and physiochemical changes of GS by Western blotting. As shown in Fig. 6A, when four hydrophobic and branched-chain amino acids were substituted in the order of steric bulk from isoleucine to alanine, the cross-reactivity of the anti-BCNT-C Ab was attenuated with an accompanying decrease in the steric bulk of the substituted amino acid, but it was not completely abolished. This result further supports our conjecture that F337 of GS is not directly involved in the interface of the antigen-Ab interaction but importantly constitutes the stereochemical environment of the epitope. Figure 6B shows a 3D layout of a region around GYFE of the common epitope of GS, which was drawn based on X-ray crystallography data of GS (PDB code 2OJW, ref.22). Note that Phe (F337) resides on the opposite side of neighboring Y336 and E338, occupying rather a space by its aromatic ring. This arrangement of F337 supports our speculation above that this amino acid is not directly involved in the contact site of the antigen-Ab interaction, but has a steric bulk effect on the stereochemical environment of the epitope. On the other hand, the cross-reactivity was approximately equal to the F337Y mutant as compared with the wild-type GS (F337) (Fig. 6A). These data suggest that the polarity of tyrosine, a hydroxyl group adduct of phenylalanine, does not significantly affect the stereochemical environment of the epitope. In conclusion, the results obtained strongly suggest that the spatial similarity of stereochemical environments formed by the core amino acids of common epitopes of GS and Bcnt is critically important in the cross-reactivity of the anti-BCNT-C Ab with GS.

**Discussion**

In this paper, we showed that the anti-BCNT-C Ab quite specifically cross-reacted with GS, which is a protein not homologous to Bcnt, in addition to the original target molecule. GS is present predominantly in the brain where it participates in the metabolic regulation of glutamate (Fig. 6A). The anti-BCNT-C Ab recognized exogenous GS expressed in HEK cells and also showed strong immunoreactivity in astrocyte of adult rat cerebellum (see Supplementary Fig. S7), consistent with the localization of GS in brain previously reported (Fig. 4B). It is most likely that strong immunoreactivities of the anti-BCNT-C Ab in Leydig cells of bovine testis and astrocytes of rat brain, which were first reacted with anti-Flag Ab to confirm loading amounts (lower panels in A and B). After stripping, (A) the membranes were reprobed with untreated (Whole), flow-through (Flow Through) or affinity-purified (GYFE fraction) Abs from the polyclonal anti-BCNT Ab by GS(332–346) peptide affinity column. (B) The membranes were reprobed with the GYFE fraction pre-incubated using BCNT-C peptide (BCNT-C(GYIE)) or BCNT-C peptide replacing GYIE with Alanine (BCNT-C(All-Ala)). The asterisk indicates non-specific band.

**Figure 5.** Isolation of the subpopulation of the polyclonal anti-BCNT-C Ab, which cross-reacts with GYFE of GS, and its affinity to GYFE of GS and GYIE of Bcnt. The subpopulation of the polyclonal anti-BCNT-C Ab cross-reacting with GYFE of GS was isolated by an affinity column using GS(332–346) peptide (see MATERIALS AND METHODS). Extracts of HEK293T cells expressing Flag-mGS (F-mGS) or Flag-mBcnt (F-mBcnt), which were adjusted to show an equal immunoreactivity to anti-Flag Ab, were subjected to Western blotting. The membrane was first reacted with anti-Flag Ab to confirm loading amounts (lower panels in A and B). After stripping, (A) the membranes were reprobed with untreated (Whole), flow-through (Flow Through) or affinity-purified (GYFE fraction) Abs from the polyclonal anti-BCNT Ab by GS(332–346) peptide affinity column. (B) The membranes were reprobed with the GYFE fraction pre-incubated using BCNT-C peptide (BCNT-C(GYIE)) or BCNT-C peptide replacing GYIE with Alanine (BCNT-C(All-Ala)). The asterisk indicates non-specific band.
common with GYIE in the immunogen peptide for the anti-BCNT-C Ab. This conjecture implies that replacement of an aromatic amino acid, Phe, of GYFE with a branched chain amino acid, Ile, maintains the epitope environment. This assumption is consistent with the results shown in Fig. 6A. GS mutants with a substitution of Phe with Ile, Leu, or Tyr showed comparable cross-reactivity of the anti-BCNT-C Ab, whereas replacement of Phe with a smaller amino acid, Val or Ala, resulted in less reactivity with the Ab, indicating that the steric bulk of each amino acid is critical for the reactivity of the epitope with the Ab. Moreover, the result also indicates that the steric bulk of the aromatic ring of F337 or Tyr of the F337Y mutant of GS, but not the polarity of amino acids, is important to maintain the stereochemical environment for the cross-reactivity of the anti-BCNT-C Ab with GS. Therefore, this result strongly suggests that Phe in GYFE (GS) and Ile in GYIE (Bcnt) play a role in maintaining the spatial arrangement of the common epitope but are not directly involved in the contact site of the antigen-Ab interaction. This speculation is consistent with a previous report that F337 resides on the opposite side of neighboring Y336 and E33822, and each is involved in binding ATP and glutamate, a substrate of GS, respectively, in the active site of the GS complex (Fig. 6B). It is also reported that though F337 in the active site of GS is highly conserved among species, it is replaced by Leu in Mycobacterium tuberculosis and Ile in Salmonella typhimurium13,22, suggesting that both the function and stereochemical environment of the active site of GS are maintained even if F337 is replaced with Leu or Ile. These data lead to the speculation that the core amino acids of the common epitopes, GYFE of GS and GYIE of Bcnt, constitute similar stereochemical environments.

It is also noted that the conjectured core amino acids of the common epitope are bracketed by charged amino acid residues such as lysine and arginine (Fig. 4C, lower left). The hydrophilicity of these charged residues may bring the core amino acids of each epitope to the surface of GS or BCNT. Elucidation of this characteristic of epitopes awaits further studies.

Figure 6. Role of Phe-337 in stereochemical environment of core amino acids of common epitope. (A) Western blotting was carried out as described in Fig. 4A using the extracts of E. coli expressing wild type GS (GS-WT) or its substitution mutants of F337 with various amino acids as shown in upper left panel and on the top of each lane. Blue letters indicate the core amino acids and red letters denote the respective substituted amino acids. (B) The inserted picture at the left top shows top-view of one pentameric ring for human GS consisted of two pentameric rings (PDB code 2OJW). The red circle depicts the location of the one of the core amino acids, GYFE, in the five identical subunits. 3D-layout of the KGYFEDR peptide in GS displaying the spatial arrangement of the common epitope region. This layout was drawn using Waals (Altif Laboratories) based on a data of X-ray crystallography (PDB code 2OJW, ref.23) of human GS.
It is well known now that whereas cross-reactions of Abs with structurally unrelated peptides of off-targets frequently occur in binding assays of Abs using small peptides, such cross-reactions rarely occur in those using protein fragments and in Western blot analysis. It has been generally believed that Abs recognize linear epitopes of target molecules under the denatured condition of SDS-PAGE, but some Abs can also react to proteins via conformational epitopes, probably depending on the protein renaturation on transferred membranes after denaturation in SDS-PAGE. The anti-BCNT-C Ab reacted to each GS mutant for Phe of GYFE in a steric bulk-dependent manner (Fig. 6A), in contrast to the loss of immunoreactivities in alanine-substituted mutants for Gly, Tyr, and Glu of GYFE (Fig. 4D). These results reflect differences in whether these amino acids exist at the contact site for the Ab (Gly, Tyr, and Glu) or not (Phe). This result, which is consistent with the configuration of the core amino acids displayed in the 3D structure of GS (Fig. 6B), suggests that Bcnt and GS are partially renatured and that their conformations are partially maintained on transferred membranes in Western blot analysis. Such renaturation of Bcnt and GS is inferred to be one of the reasons why we were able to elucidate the similarity of stereochemical environments between GYIE and Bcnt and GYFE of GS by Western blot analysis.

Recent reports including this paper indicate that cross-reactions of Abs with off-target molecules cannot be avoided, even when choosing a very specific amino acid sequence as an immunogen. Therefore, we have to pay attention to the fact that Abs do not necessarily recognize only “on-targets” but potentially react with “off-targets” that comprise similar stereochemical or physicochemical environments as that of on-target molecules. Recent advances in computational and bioinformatic analyses using extensively accumulated data of epitope-paratope interfaces make it possible to group T cell receptors of common specificity using grouping algorithms of lymphocyte interactions by paratope hotspots. Furthermore, these advances have also revealed the functional redundancy of epitopes based on physicochemical similarities at a level of amino acid residues involved in the antigenic cross-reaction. In addition to these accumulated data, further comprehensive understanding of the physicochemical environment of epitope-paratope interfaces including both “on-targets” and “off-targets” may make it possible to evaluate and predict more accurately antigenicity and immunogenicity, and these advances will bring about therapeutic Abs and vaccines with high specificity and without adverse effects.

Materials and Methods

Ethical approval. All the genetic recombination experiments and all the animal experiments in the present study were approved by the Genetic Recombination Experiment Safety Committee and the Animal Care and Use Committee, respectively, of Tokushima Bunri University.

Reagents. Generation of anti-BCNT-C Ab, anti-mBcnt-N Ab, and anti-Bcnt-Cter Ab is described in Supplementary Materials and Methods. Abs against Flag tag (DYKDDDDK tag; 014-22383) and GS (GTX109121) were obtained from Wako Pure Chemical Industries and GeneTex, respectively. Unstained or prestained SDS-PAGE molecular weight standard markers (Bio-Rad) were used differently for each experiment.

Construction of expression vectors for mGS and mBcnt. A plasmid carrying Myc-tagged mGS was a gift from Dr. T. Araki (Natl. Inst. Neurosci., Tokyo). Using cloning primers (see Supplementary Table S3-1), mGS and mBcnt cDNAs were amplified from cDNA, which was reverse transcribed from the total RNA of the brain of an adult male C57BL/6J mouse using dT-primer and inserted into mammalian expression vectors, as described in Supplementary Materials and Methods. All the expression vectors for GS mutants were constructed and used as described in Supplementary Materials and Methods. Among GS mutants, F337A and an all-Ala replacement mutants of 355–358 (GYFE) were confirmed by MALDI-TOF MS and LC-MS/MS after digestion with Asp-N protease or trypsin.

Cell culture and transfection. HEK-293T cells were maintained at 37 °C, 5% CO2, in high glucose (4.5 g D-glucose/L) DMEM-GlutaMAX-I (Thermo Fisher Scientific) supplemented with 10% Fetal bovine serum and 50 mg/L gentamicin. HEK-293T cells were plated in 6-well plates at ~60% confluency and transfected with a expression vector DNA (0.5 μg/well) using PLUS reagent (0.5 μL/well) and Lipofectamine LTX reagent (1.2 μL/well) (Thermo Fisher Scientific).

Preparation of extracts of E. coli expressing GS and its mutants. Culture of E. coli and induction of coded molecules by cDNAs in pCold II vector were described previously. E. coli were harvested and washed with PBS by centrifugation at 5,000 × g for 5 min. After addition of 50 μL H2O per pellet derived from 1 mL culture, resuspended cells were mixed with an equal volume of 2-fold concentrated lysis buffer (40 mM Tris-HCl buffer (pH 7.6) containing 2% SDS) and immediately boiled for 3 min. Extracts were sonicated by a Bioruptor (BM Equipment) in an ice-water bath (15 × 10 s pulses at 10 s intervals) and followed by centrifugation at 28,000 × g for 10 min. Supernatants were subjected to Western blot analysis.

Immunoblotting. Procedures of SDS-PAGE and blotting onto membranes were essentially the same as previously described except that a low fluorescence membrane (Immobilon-FL, Merck) was used in the fluorescent method. Immunodetections were carried out by chemiluminescent, colorimetric, and fluorescent methods using horseradish peroxidase (HRP)-, alkaline phosphatase (AP)-, and fluorescent dye-conjugated secondary Abs, respectively. The secondary IgGs used are listed in Supplementary Materials and Methods. Tris-buffered saline supplemented with 0.1% Tween 20 (TBT) was used as a wash buffer in all three methods. In the chemiluminescent method, immunoreaction was carried out in TBT containing 5% or 10% skim milk and the immunoreactivity was detected by a scanner (GeneGenome, Syngene Bio Imaging) using Immobilon (Merck), ImmunostAR Zeta, or LD (Wako Chem.) as a substrate. In the colorimetric method, immunoreaction was carried out in TBT containing 0.2% casein (I-Block, Thermo Fisher Scientific), and the immunoreactivity was detected by an LAS-3000 Imager (Fuji-Film) using 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (Sigma) as a substrate.
a chromogenic substrate. In the fluorescent method, the immune reaction was carried out in TBT containing 0.2% casein, and the immunoreactivity was detected by an Odyssey 700 CLX Infrared Imaging system (LI-COR Biosciences). Membranes of bound Abs for reprobing were stripped by shaking membranes in 62.5 mM Tris-HCl (pH 6.8), 2% SDS, and 100 mM 2-mercaptoethanol for 1 h at 70 °C. To avoid inhibition by former enzymatic reaction products, reprobing was carried out only after detection by the fluorescent method.

**Isolation of a subpopulation of the polyclonal anti-BCNT-C Ab, which cross-reacts with GYFE of GS.** GS(332–346) peptide, acetylated-EKKGYFEDRRPSANC-COOH (0.75 mg, 91.2% purity, obtained from AnyGen), was coupled to 1 mL of SulfoLink Coupling Resin (Thermo Fisher Scientific) packed in a column (MoBiTec) according to a manufacturer's protocol. The anti-BCNT-C Ab of 4.45 mg diluted in 10 mL with Binding/Wash buffer (20 mM PBS (pH 7.0) containing 0.05% sodium azide) passed through the column 5 times and a flow-through fraction was obtained. After washing the resin with 50 mL of Binding/Wash buffer, the bound fraction (GYFE fraction) was eluted with 6 mL of 100 mM Glycine (pH 3.0) and immediately neutralized with Neutralization buffer (1 M Tris–HCl (pH 8.5), 1.5 M NaCl, 5 mM EDTA). The protein concentrations of the binding fraction (GYFE fraction) and the flow-through fraction were determined by Bicinchoninic acid (BCA) assay kit (Thermo Fisher Scientific) using bovine serum albumin as a standard after buffer exchange and concentration by ultrafiltration using Amicon Ultra-4, 30 kDa (Merck Millipore). Their protein concentrations were 0.78 mg and 2.80 mg, respectively, with total recovery of 80.7%.

**Competitive experiments for evaluation of the specificity of the GYFE fraction to GYIE of Bcnt.** Extracts of HEK293T cells expressing Flag-mGS (F-mGS) or Flag-mBcnt (F-mBcnt) were adjusted to show an equal immunoreactivity to anti-Flag Ab, then subjected to Western blotting. The membrane was first reacted with anti-Flag Ab to confirm loading amounts. After stripping, the membranes were reprobed with the GYFE fraction (1.33 nM as a IgG) pre-incubated with BCNT-C peptide (NH2-EELAIHNRGKGYIERKA-NH2, 92.3% purity, from AnyGen) or BCNT-C peptide replacing GYIE with Alanine (NH2- EELAIHNRGKEAAAARKA-NH2, 98.3% purity, from AnyGen) at a final concentration of 25μM.

**Mass spectroscopy analysis.** The CBB stained protein bands in the gel were excised and de-stained. The protein bands were digested with trypsin (TPCK-treated, Worthington Biochemical) at 37 °C for 12 h in 50 mM Tris-HCl (pH 8.0). The digests were analyzed by nano LC–MS/MS using a Q Exactive mass spectrometer exactly as described previously11.

**Immunocytochemistry.** Transfected HEK-293T cells (see “Cell culture and transfection”) were plated on glass slides (Millicell EZ 4-well glass slides, Merck Millipore) coated with poly-D-lysine (Sigma-Aldrich). After 30 h, the cultured cells were fixed with ice-cold 4% paraformaldehyde (PFA) in 0.1 M phosphate-buffer (PB, pH 7.2) for 15 min and subjected to double immunostaining as described in the “Immunohistochemistry” section of Supplementary Materials and Methods. First, cells were stained with guinea pig anti-BCNT-C Ab (1:500) and visualized by FITC-conjugated donkey anti-guinea pig IgG (1:50, Jackson ImmunoResearch). The second staining was done with rabbit anti-GS Ab (1:1000, GeneTex) visualized by Cy3-conjugated donkey anti-rabbit IgG (1:200, Jackson ImmunoResearch). Immunostained cells were examined by confocal laser scanning microscopy (FV10000, Olympus).

**References**

1. Chiavenna, S. M., Jaworski, J. P. & Vendrell, A. State of the art in anti-cancer mAbs. *J Biomed Sci* 24, 15 (2017).
2. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. *Science* 348, 56–61 (2015).
3. Thomas, A., Teicher, B. A. & Hassan, R. Antibody-drug conjugates for cancer therapy. *Lancet Oncol* 17, e254–e262 (2016).
4. Rossi, D., Modena, V., Sciascia, S. & Roccacello, D. Rheumatoid arthritis: Biological therapy other than anti-TNF. *Int Immunopharmacol* 27, 185–188 (2015).
5. Zampeli, E., Vlachoyiannopoulos, P. G. & Tzioufas, A. G. Treatment of rheumatoid arthritis: Unraveling the conundrum. *J Autoimmun* 65, 1–18 (2015).
6. Foyen, O. et al. Off-target activity of TNF-alpha inhibitors characterized by proteinbiochips. *Anal Bioanal Chem* 391, 1713–1720 (2008).
7. Mahmud, M. N. et al. A multispecific monoclonal antibody G2 recognizes at least three completely different epitope sequences with high affinity. *Protein Sci* 26, 2162–2169 (2017).
8. Koenig, P., Sanower, S., Lee, C.-V. & Fuh, G. Tuning the specificity of a Two-in-One Fab against three angiogenic antigens by fully utilizing the information of deep mutational scanning. *Mabs* 9, 959–967 (2017).
9. Forsström, B. et al. Proteome-wide epitope mapping of antibodies using ultra-dense peptide arrays. *Mol Cell Proteomics* 13, 1585–1597 (2014).
10. Peng, H. P., Lee, K. H., Jian, J. W. & Yang, A. S. Origins of specificity and affinity in antibody-protein interactions. *Proc Natl Acad Sci USA* 111, E2656–2663 (2014).
11. Iwashita, S. et al. Mammalian Bcnt/Cfdp1, a potential epigenetic factor characterized by an acidic stretch in the disordered N-terminal and Ser250 phosphorylation in the conserved C-terminal regions. *Biosci Rep* 35, e00228 (2015).
12. Iwashita, S. et al. A transposable element-mediated gene divergence that directly produces a novel type bovine Bcnt protein including the endonuclease domain of RTE-1. *Mol Biol Evol* 20, 1556–1563 (2003).
13. Eisenberg, D., Gill, H. S., Pfluegl, G. M. & Rotstein, S. H. Structure-function relationships of glutamine synthetases. *Biochim Biophys Acta* 1477, 122–45 (2000).
14. Rose, C. F., Verkhratsky, A. & Purpara, V. Astrocyte glutamine synthetase: pivotal in health and disease. *Biochem Soc Trans* 41, 1518–1524 (2013).
15. Peri, C., Morra, G. & Colombo, G. Surface energetics and protein-protein interactions: analysis and mechanistic implications. *Sci Rep* 6, 24035 (2016).
16. Urayama, O., Murakoshi, T. & Ikawa, Y. K rev-1 protein is abundantly expressed in the rat spinal cord. *Biochem Biophys Acta* 1243, 446–452 (1995).
17. Saitoh, F. & Araki, T. Proteasomal degradation of glutamine synthetase regulates Schwann cell differentiation. *J Neurosci* 30, 1204–1212 (2010).
18. Kamei, Y. et al. FOXO1 activates glutamine synthetase gene in mouse skeletal muscles through a region downstream of 3′-UTR: possible contribution to ammonia detoxification. *Am J Physiol Endocrinol Metab* **307**, E485–E493 (2014).

19. Norenberg, M. D. & Martínez-Hernandez, A. Fine structural localization of glutamine synthetase in astrocytes of rat brain. *Brain Res* **161**, 303–310 (1979).

20. Kuliwuwicz-Nawrot, M., Syková, E., Chvátal, A., Verkhratsky, A. & Rodriguez, J. J. Astrocytes and glutamate homeostasis in Alzheimer’s disease: a decrease in glutamate transporter-1, in the prefrontal cortex. *ASN Neuro* **5**, 273–282 (2013).

21. Huyghe, D. et al. Glutamine synthetase stability and subcellular distribution in astrocytes are regulated by γ-aminobutyric type B receptors. *J Biol Chem* **289**, 28808–28815 (2014).

22. Krajewski, W. et al. Crystal structures of mammalian glutamine synthetases illustrate substrate-induced conformational changes and provide opportunities for drug and herbicide design. *J Mol Biol* **375**, 217–228 (2008).

23. Jayakumar, A. R. & Norenberg, M. D. Glutamine synthetase: role in neurological disorders. *Adv Neurobiol* **13**, 327–350 (2016).

24. Iwashita, S., Nakashima, K., Sasaki, M., Osada, N. & Song, S. Y. Multiple duplication of the bocentaur gene family, which recruits the APE-like domain of retrotransposon: Identification of a novel homolog and distinct cellular expression. *Gene* **435**, 88–95 (2009).

25. Holash, J. A., Harik, S. I., Perry, G. & Stewart, P. A. Barrier properties of testis microvessels. *Proc Natl Acad Sci USA* **90**, 11069–11073 (1993).

26. Forström, B. et al. Dissecting antibodies with regards to linear and conformational epitopes. *PLoS One* **10**, e0121673 (2015).

27. Zhou, Y. H., Chen, Z., Purcell, R. H. & Emerson, S. U. Positive reactions on Western blots do not necessarily indicate the epitopes on antigens are continuous. *Immunol Cell Biol* **85**, 73–78 (2007).

28. McIntush, E. W. Response: ‘Antibody crossreactivity between the tumour suppressor PHLPP1 and the proto-oncogene β-catenin’. *EMBO reports* **14**, 494–496 (2013).

29. Glanville, J. et al. Identifying specificity groups in the T cell receptor repertoire. *Nature* **547**, 94–98 (2017).

30. Caoli, S. E. Expressing redundancy among linear-epitope sequence data based on residue-level physicochemical similarity in the context of antigenic cross-reaction. *Adv Bioinformatics* 1276594 (2016).

Acknowledgements
We thank Dr. Toshiyuki Araki for gift of GS-myc plasmid and Drs. Mathias Uhlen, Howard W. Davidson, Eiji Kinoshita, Ichiro N. Maruyama, Daniel M. Roberts, and Masami Kusunoki for discussion. We also thank Rie Fujii and Dr. Tomoko Warita for supporting experimental works. We are grateful to Dr. Makoto Iwata for critical reading the manuscript and comments.

Author Contributions
N.K., S.I. and S.Y.S. conceived the study and wrote the manuscript. K.N., S.I., C.K. and S.Y.S. executed experiments and T.S. and N.D. conducted MS analysis. T.K. performed 3D analysis of epitope and Y.K., M.S., O.U. and Y.O.I. contributed reagents. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-51350-2.

Competing Interests: The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019